RU2010101093A - Способы диагностики и лечения рака - Google Patents

Способы диагностики и лечения рака Download PDF

Info

Publication number
RU2010101093A
RU2010101093A RU2010101093/10A RU2010101093A RU2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093/10 A RU2010101093/10 A RU 2010101093/10A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A
Authority
RU
Russia
Prior art keywords
subject
rrm1
cancer
expression
level
Prior art date
Application number
RU2010101093/10A
Other languages
English (en)
Russian (ru)
Inventor
Джерольд БЕПЛЕР (US)
Джерольд БЕПЛЕР
Original Assignee
Юниверсити Оф Саут Флорида (Us)
Юниверсити Оф Саут Флорида
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Саут Флорида (Us), Юниверсити Оф Саут Флорида filed Critical Юниверсити Оф Саут Флорида (Us)
Publication of RU2010101093A publication Critical patent/RU2010101093A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010101093/10A 2007-06-15 2008-06-13 Способы диагностики и лечения рака RU2010101093A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US60/944,157 2007-06-15
US3955508P 2008-03-26 2008-03-26
US61/039,555 2008-03-26

Publications (1)

Publication Number Publication Date
RU2010101093A true RU2010101093A (ru) 2011-07-20

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010101093/10A RU2010101093A (ru) 2007-06-15 2008-06-13 Способы диагностики и лечения рака

Country Status (12)

Country Link
US (1) US20090017012A1 (enExample)
EP (1) EP2171086B1 (enExample)
JP (1) JP5479332B2 (enExample)
KR (1) KR20100044780A (enExample)
CN (1) CN101815793A (enExample)
AU (1) AU2008266048A1 (enExample)
BR (1) BRPI0813364A2 (enExample)
CA (1) CA2690865A1 (enExample)
ES (1) ES2401475T3 (enExample)
MX (1) MX2009013646A (enExample)
RU (1) RU2010101093A (enExample)
WO (1) WO2008157353A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2008146868A (ru) 2006-05-18 2010-06-27 Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) Система и способ определения персонализированого медицинского вмешательства при болезненном состоянии
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
JP5024736B2 (ja) 2009-10-15 2012-09-12 住友電気工業株式会社 発電システム
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
MX369728B (es) 2010-03-29 2019-11-20 Abraxis Bioscience Llc Métodos para mejorar suministro de fármacos y efectividad de agentes terapéuticos.
EP2556172A4 (en) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
EP3396573A4 (en) * 2015-10-26 2019-08-28 Cipherome METHOD AND SYSTEM FOR SELECTING AN INDIVIDUALLY ADJUSTED MEDICAMENT WITH THE INFORMATION OF THE VARIATIONS OF A GENOMIC NUCLEOTIDE SEQUENCE AND SURVIVAL INFORMATION OF A CANCER PATIENTS
WO2022011207A1 (en) * 2020-07-10 2022-01-13 Progenics Pharmaceutical, Inc Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
US6416987B1 (en) * 1997-02-04 2002-07-09 Sloan Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
EP1191096B1 (en) * 1999-06-28 2011-10-12 Yusuke Nakamura Ovel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2004031408A1 (en) * 2002-09-30 2004-04-15 F.Hoffmann-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
KR20060120063A (ko) * 2003-09-29 2006-11-24 패스워크 인포메틱스 아이엔씨 생물학적 특징의 탐지 시스템 및 생물학적 특징 탐지 방법
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測

Also Published As

Publication number Publication date
CA2690865A1 (en) 2008-12-24
ES2401475T3 (es) 2013-04-19
EP2171086A1 (en) 2010-04-07
EP2171086A4 (en) 2010-10-13
MX2009013646A (es) 2010-03-30
JP5479332B2 (ja) 2014-04-23
KR20100044780A (ko) 2010-04-30
US20090017012A1 (en) 2009-01-15
AU2008266048A1 (en) 2008-12-24
WO2008157353A1 (en) 2008-12-24
EP2171086B1 (en) 2012-12-19
CN101815793A (zh) 2010-08-25
JP2010530746A (ja) 2010-09-16
BRPI0813364A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
RU2010101093A (ru) Способы диагностики и лечения рака
US8198024B2 (en) Gene expression markers for colorectal cancer prognosis
ES2488845T5 (es) Predicción de la probabilidad de recidiva de cáncer
JP2010530746A5 (enExample)
US20090258795A1 (en) Gene expression markers for prediction of patient response to chemotherapy
US20100285980A1 (en) Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
Wu et al. Long noncoding RNA HOTTIP expression predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation
CN107488726A (zh) 一种肾癌预后评估生物标志物及其检测试剂和应用
CN116761899A (zh) 结直肠癌分子分型及生存风险基因群及诊断产品和应用
Laurenti et al. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia
Chen et al. Highly expressed circ_0000285 from serum and cervical exfoliated cells as a novel biomarker for the diagnosis of early stage-cervical cancer
CN115521985A (zh) 浸润性cd8+t细胞的标志物组合及其应用
Xu et al. Identification of an Excellent PCR-Based Classifier to Predict Tumor Relapse in Stage II/III Colorectal Cancer and Its Clinical Application Irrespective of Consensus Molecular Subtypes
CN121137157A (zh) 一种评估上皮性卵巢癌复发风险的试剂的用途
CN112368399A (zh) miRNA用于高级别浆液性卵巢癌治疗护理的预测和预后用途
Wu et al. Preoperative Immune Cells Infiltration in the Tumor Microenvironment as a Prediction and Prognostic Factor for Postoperative Recurrence in Hepatocellular Carcinoma
HK1120089B (en) Gene expression markers for colorectal cancer prognosis
HK1167004A (en) Gene expression markers for colorectal cancer prognosis
HK1165507A (en) Gene expression markers for colorectal cancer prognosis
HK1166352A (en) Gene expression markers for colorectal cancer prognosis
HK1162613A (en) Gene expression markers for colorectal cancer prognosis
HK1166351A (en) Gene expression markers for colorectal cancer prognosis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130128